

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-17 (Canceled)

18. (new) An antibody which immunospecifically binds an epitope, wherein said epitope is recognized by the anti-human uPAR monoclonal antibody 3936 and wherein said antibody is conjugated to a cytotoxic or cytostatic compound.
19. (new) The antibody of claim 18, wherein said antibody is a human antibody.
20. (new) The antibody of claim 18, wherein said antibody is a humanized antibody.
21. (new) The antibody of claim 18, wherein said antibody is a single chain antibody, a Fab fragment, a F(ab')₂ fragment, an anti-idiotypic antibody, or an epitope binding fragment.
22. (new) The antibody of claim 18, 19 or 20, wherein said antibody is a monoclonal antibody.
23. (new) The antibody of claim 18, wherein said antibody is the monoclonal antibody 3936.
24. (new) The antibody of claim 18 or 23, wherein the cytotoxic or cytostatic compound is saporin, A-chain ricin, A-chain cholera toxin, or an antibiotic.
25. (new) The antibody of claim 18 or 23, wherein the cytotoxic or cytostatic compound is an antimetabolite.
26. (new) A pharmaceutical composition comprising the antibody of claim 18, 19, 20, 21 or 23, and a pharmaceutically acceptable carrier.
27. (new) A pharmaceutical composition comprising the antibody of claim 25 or 26, and a pharmaceutically acceptable carrier.
28. (new) A humanized antibody which immunospecifically binds an epitope, wherein said epitope is recognized by the anti-human uPAR monoclonal antibody 3936.

29. (new) A pharmaceutical composition comprising the humanized antibody of claim 28, and a pharmaceutically acceptable carrier.